Peptide compositions for targeting adipose tissue

Details Peptide compositions for targeting adipose tissue Peptide compositions for targeting adipose tissue

2007-05-29

2011-11-29

Tsang, Cecilia J (Department: 1654)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C514S021300, C435S091400

Reexamination Certificate

active

08067377

ABSTRACT:
The present invention concerns methods and compositions for in vivo and in vitro targeting. A large number of targeting peptides directed towards human organs, tissues or cell types are disclosed. The peptides are of use for targeted delivery of therapeutic agents, including but not limited to gene therapy vectors. A novel class of gene therapy vectors is disclosed. Certain of the disclosed peptides have therapeutic use for inhibiting angiogenesis, inhibiting tumor growth, inducing apoptosis, inhibiting pregnancy or inducing weight loss. Methods of identifying novel targeting peptides in humans, as well as identifying endogenous receptor-ligand pairs are disclosed. Methods of identifying novel infectious agents that are causal for human disease states are also disclosed. A novel mechanism for inducing apoptosis is further disclosed.

REFERENCES:
patent: 4472509 (1984-09-01), Gansow et al.
patent: 4912040 (1990-03-01), Kaufman et al.
patent: 4931053 (1990-06-01), L'Esperance, Jr.
patent: 5021236 (1991-06-01), Gries et al.
patent: 5081034 (1992-01-01), Bevilasqua et al.
patent: 5098833 (1992-03-01), Lasky et al.
patent: 5188964 (1993-02-01), McGuire et al.
patent: 5206347 (1993-04-01), Ruoslahti et al.
patent: 5216131 (1993-06-01), Lasky et al.
patent: 5223409 (1993-06-01), Ladner et al.
patent: 5225538 (1993-07-01), Capon et al.
patent: 5259380 (1993-11-01), Mendes et al.
patent: 5270163 (1993-12-01), Gold et al.
patent: 5288846 (1994-02-01), Quertermous et al.
patent: 5304640 (1994-04-01), Asky et al.
patent: 5415874 (1995-05-01), Bender et al.
patent: 5428130 (1995-06-01), Capon et al.
patent: 5453362 (1995-09-01), Lamarco et al.
patent: 5463026 (1995-10-01), Nakamura et al.
patent: 5464436 (1995-11-01), Smith
patent: 5492807 (1996-02-01), Santi
patent: 5506126 (1996-04-01), Seed et al.
patent: 5536814 (1996-07-01), Ruoslahti et al.
patent: 5585277 (1996-12-01), Bowie et al.
patent: 5622699 (1997-04-01), Ruoslahti et al.
patent: 5670312 (1997-09-01), Santi
patent: 5688692 (1997-11-01), Jat et al.
patent: 5688935 (1997-11-01), Stephens et al.
patent: 5705610 (1998-01-01), Zuckermann et al.
patent: 5750344 (1998-05-01), Doyle
patent: 5840841 (1998-11-01), Zuckermann et al.
patent: 5866759 (1999-02-01), Jat et al.
patent: 5902598 (1999-05-01), Chen et al.
patent: 5955572 (1999-09-01), Ruoslahti et al.
patent: 6057098 (2000-05-01), Buechler et al.
patent: 6068829 (2000-05-01), Ruoslahti et al.
patent: 6174861 (2001-01-01), O'Reilly et al.
patent: 6184973 (2001-02-01), Baer et al.
patent: 6215550 (2001-04-01), Baer et al.
patent: 6232440 (2001-05-01), Hillman et al.
patent: 6271196 (2001-08-01), O'Brien
patent: 6300064 (2001-10-01), Knappik et al.
patent: 6350855 (2002-02-01), Tobin
patent: 6399384 (2002-06-01), Jat
patent: 6458381 (2002-10-01), Sourovoi et al.
patent: 6528281 (2003-03-01), Tobin
patent: 6576239 (2003-06-01), Ruoslahti et al.
patent: 6881825 (2005-04-01), Robbins et al.
patent: 7452964 (2008-11-01), Pasqualini et al.
patent: 2001/0046498 (2001-11-01), Rouslahti et al.
patent: 2003/0113320 (2003-06-01), Ruoslahti et al.
patent: 2004/0214272 (2004-10-01), La Rosa et al.
patent: 2005/0191294 (2005-09-01), Arap et al.
patent: 19605175 (1997-08-01), None
patent: 0639584 (1998-04-01), None
patent: 4026631 (1992-01-01), None
patent: 2004-546020 (2004-12-01), None
patent: WO 92/00091 (1991-07-01), None
patent: WO 92/03461 (1992-03-01), None
patent: WO 92/06191 (1992-04-01), None
patent: WO 94/28424 (1994-12-01), None
patent: WO 95/14714 (1995-06-01), None
patent: WO 96/34874 (1996-11-01), None
patent: WO 96/34875 (1996-11-01), None
patent: WO 97/10507 (1997-03-01), None
patent: WO 97/19954 (1997-05-01), None
patent: WO 97/39021 (1997-10-01), None
patent: WO 98/10795 (1998-03-01), None
patent: WO 98/39469 (1998-09-01), None
patent: WO 99/04813 (1999-02-01), None
patent: WO 97/30024 (1999-09-01), None
patent: WO 99/46284 (1999-09-01), None
patent: WO 99/57311 (1999-11-01), None
patent: WO 00/14215 (2000-03-01), None
patent: WO 01/42276 (2001-06-01), None
patent: WO 01/53342 (2001-07-01), None
patent: WO 02/02055 (2002-01-01), None
patent: WO 02/20722 (2002-03-01), None
patent: WO 02/20723 (2002-03-01), None
patent: WO 02/20769 (2002-03-01), None
patent: WO 02/20822 (2002-03-01), None
patent: WO 03/022991 (2003-03-01), None
Hussain, 1995, Journal of Pharmaceutical Sciences, 84, 62-64.
M. Nomizu, et al. J. Biol. Chem. (1998) 273(46), pp. 32491-32499.
La Rosa (STN search notes), 2004 (US 2004/0214272), 2 pages, [printed on Jan. 24, 2011].
Kolonin et al., “Targeting physiological and pathological blood vessel formation with in vivo phage display,”Proc. Am. Assoc. Cancer Res., 42:822-823, 2001.
Marchio et al., “Aminopeptidase A-Binding Peptides Regulate Endothelial Cell Function and Inhibit Angiogenesis,”Tumori, 86:13, 2000.
St. Hilaire et al., “The Substrate specificity of a recombinant cystein protease fromLeishmania mexicana: application of a combinatorial peptide library approach,”Chembiochem: A European Journal of Chemical Biology, 1:115-122, 2000.
European Office Action, issued in European Application No. 01 968 603.9-2405, dated Jan. 8, 2008.
Uniprot Accession No. Q9R1H5 Insulin Receptor Rattus norvegicus fragment, integrated in the database 1.5.2000.
European Search Report issued in Application No. 08016646.5-2405, dated Jan. 28, 2009.
Marchiò et al., “Aminopeptidase A is a functional target in angiogenic blood vessels,”Cancer Cell, 5:151-162, 2004.
Aiello et al., “Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins,”Proc. Natl. Acad. Sci., USA, 92(23):10457-10461, 1995.
Aiello et al., “Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders,”N. Eng. J Med., 331(22):1480-1487, 1994.
Alliot et al., “Brain parenchyma vessels and the angiotensin system,”Brain Res., 830:101-112, 1999.
Alliot et al., “Pericytes and periendothelial cells of brain parenchyma vessels co-express aminopeptidase N, aminopeptidase A, and nestin,”J. Neurosci. Res., 58:367-378, 1999.
Alon et al., “Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity,”Nat. Med., 1:1024-1028, 1995.
Alonso and Maroto, “Plants as ‘chemical factories’ for the production of polyunsaturated fatty acids,”Biotechnology Advances, 18:481-497, 200, 2000.
Andrade et al., “Angiotensin-II-induced angiogenesis in sponge implants in mice,”Int. J. Microcirc. Clin. Exp., 16(6):302-307, 1996.
Arap et al., Steps toward mapping the human vasculature by phage display,Nature Med., 8(2):121-127, 2002.
Arap et al., “Cancer treatment by targeted drug delivery to tumor vasculature in a mouse model,”Science, 279:377-380, 1998.
Arap et al., “Cell surface expression of the stress response chaperone GRP78 enables tumor targeting by circulating ligands,”Cancer Cell, 6:275-284, 2004.
Arap et al., “Chemotherapy targeted to tumor vasculature ,”Curr. Opin. Onclol., 10(6):560-565, 1998.
Arap et al., “Targeting the prostate for destruction through a vascular address,”Proc. Natl. Acad. Sci., USA, 99:1527-1531, 2002.
Arden, “The absence of diabetic retinopathy in patients with retinitis pigmentosa: implications for pathophysiology and possible treatment.,”Br. J. Ophthalmol., 85:366-370, 2001.
Asako et al., “Organic solvent tolerance and antibiotic resistance increased by overexpression of marA inEscherichia coli,” Applied Environmental Microbiology, 63(4):1428-1433, 1997.
Assmann et al., “A nephritogenic rat monoclonal antibody to mouse aminopeptidase A. Induction of massive albuminuria after a single intravenous injection,”J. Exp. Med., 175:623-635, 1992.
Atkins et al., “Coordinated cytokine expression by stromal and hematopoietic c

Affiliated with

Also associated with

Rating

Peptide compositions for targeting adipose tissue does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide compositions for targeting adipose tissue, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide compositions for targeting adipose tissue will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4305221